The majority of patients with thrombocytopenic purpura usually have a good prognosis and do not affect their life expectancy, while only a few patients may develop serious complications that eventually lead to death. Thrombocytopenic purpura is a common clinical thrombocytopenic disorder, mainly due to excessive destruction of platelets in the peripheral blood due to the body’s production of autoantibodies against platelets. As a result of thrombocytopenia, it often manifests clinically as bleeding symptoms in various parts of the body, which may include petechiae and petechiae on the skin mucosa, as well as nasal bleeding, gum bleeding, oral mucosal bleeding, and even bleeding from internal organs. About 80% of the patients with thrombocytopenic purpura can be cured, and only a small number of patients can have recurrent attacks. Therefore, for the majority of patients with thrombocytopenic purpura, it does not affect their survival time, and only a very small number of patients with thrombocytopenic purpura may die from intracranial hemorrhage. In addition, thrombocytopenic purpura patients, life also need to pay attention to avoid trauma.